Truist analyst Danielle Brill initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $68 price target The firm views the company’s pipeline as “differentiated,” with MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria. Both programs use clinically validated mechanisms but are engineered to deliver potential advantages over leading competitors, the analyst tells investors in a research note. Truist sees “meaningful upside” for Maze shares as these assets advance through the clinic.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics price target raised to $58 from $43 at Wedbush
- Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
- Maze Therapeutics initiated with an Outperform at Mizuho
- Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
- Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside